NCT05759520View on ClinicalTrials.gov

Phase III Clinical Trial of 13-valent Pneumococcal Conjugate Vaccine (Multivalent Conjugate) in Infants

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

1,800

Participants

Timeline

Start Date

November 4, 2022

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2025

Conditions
Streptococcus Pneumoniae Infection
Interventions
BIOLOGICAL

13-valent pneumococcal conjugate vaccine (multivalent conjugate)

the 2-month-old experimental group and the 3-month-old group received the experimental vaccine

BIOLOGICAL

Prevenar 13

the 2-month-old control group received the active control vaccine

Trial Locations (5)

530000

Binyang County Center for Disease Control and Prevention, Nanning

Wuming District Center for Disease Control and Prevention, Nanning

542800

Zhongshan County Center for Disease Control and Prevention, Hezhou

545000

Luzhai County Disease Prevention Control Center, Liuzhou

547000

Yizhou District Disease Prevention Control Center, Hechi

All Listed Sponsors
lead

Fosun Adgenvax Biopharmaceutical Co.,Ltd.

INDUSTRY